ValuEngine upgraded shares of Theratechnologies (OTCMKTS:THERF) from a hold rating to a buy rating in a research note released on Thursday.
Theratechnologies stock traded up $0.05 during mid-day trading on Thursday, hitting $7.10. 18,818 shares of the company were exchanged, compared to its average volume of 46,873. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.89 and a quick ratio of 2.52. Theratechnologies has a 12-month low of $5.15 and a 12-month high of $11.25.
Theratechnologies (OTCMKTS:THERF) last posted its quarterly earnings results on Thursday, February 21st. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $13.85 million during the quarter. Theratechnologies had a negative return on equity of 7.73% and a negative net margin of 10.42%.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.
Featured Story: What is the Stochastic Momentum Index (SMI)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.